Narrow margin excision of T1a melanoma not associated with recurrence or melanoma-specific mortality
1. Wide local excision of T1a melanoma near critical structures with narrow (5-mm) margins was not associated with worse outcomes....
Dermatology
Vitamin D supplementation during winter did not improve psoriasis severity
1. Weekly vitamin D (vitD) supplementation throughout winter did not significantly affect psoriasis severity. 2. Compared to previous studies, 25-hydroxyvitamin...
Healthcare Barriers and Hidradenitis Suppurativa: The Patient Experience
1. Patients with hidradenitis suppurativa (HS) experience compounding healthcare barriers related to disease activity, employment, healthcare coverage, costs, healthcare professionals’...
Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
1. In two phase three trials, 16 weeks of lebrikizumab treatment effectively treated adolescents and adults with moderate-to-severe atopic dermatitis....
Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors
1. There is a 71% lower risk of disease progression or death in the nirogacestat group than in the placebo...
Secukinumab reduces symptoms of moderate-to-severe hidradenitis suppurativa
1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared to those receiving placebo. 2. Secukinumab was well-tolerated,...
Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the adjuvant-only group (72% vs 49%). 2....
Difelikefalin reduces pruritus in adults with notalgia paresthetica
1. In this randomized controlled trial, difelikefalin reduced pruritus intensity in patients with notalgia paresthetica over eight weeks of treatment...
Risk of hydroxychloroquine retinopathy increases with longer use and higher dosage
1. In this retrospective cohort study, the incidence of hydroxychloroquine retinopathy was 2.5% at 10 years, increasing to 8.6% at...
Rocatinlimab may be effective in the treatment of moderate-to-severe atopic dermatitis
1. At week 16, all rocatinlimab groups reported significant improvements in eczema severity. 2. Most treatment-related adverse events were mild-to-moderate,...
